SciSparc unit NeuroThera Labs reports SCI-210 autism trial enrollment momentum
SciSparc subsidiary NeuroThera Labs said it has achieved significant enrollment momentum in its SCI-210 autism clinical trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
SciSparc subsidiary NeuroThera reports enrollment momentum in SCI-210 trial
SciSparc says its NeuroThera Labs has achieved significant enrollment momentum in its SCI-210 autism clinical trial.